Co-Diagnostics, Inc. (NASDAQ: CODX) has released its financial results for the year ended December 31, 2025, revealing a substantial net loss of $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share in 2024. The company attributed this increase in losses primarily to an $18.9 million non-cash impairment charge related to the revaluation of intangible assets and a significant decline in revenue, which fell to $0.6 million from $3.9 million in the previous year. The decrease in revenue was largely due to lower grant revenue, reflecting challenges in securing funding and generating sales. Operating expenses also rose to $50.6 million from $43.0 million in 2024, further exacerbating the financial strain on the company. Despite these challenges, Co-Diagnostics highlighted its ongoing efforts to advance its clinical pipeline and regulatory pathways for its PCR platform, as well as its joint ventures in India and Saudi Arabia. The company remains focused on executing its strategy to enhance its market position and drive future growth. However, the significant losses and operational challenges may raise concerns among investors regarding the company's financial health and ability to recover in the near term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.